Survey finds strong veterinary optimism on stem cell therapy

A new survey from the American Animal Hospital Association, conducted with Gallant, found broad optimism among U.S. small-animal veterinary professionals about stem cell therapy for inflammatory disease. In the survey of more than 1,000 respondents, 95% said stem cell therapy is likely to become part of the standard spectrum of care for inflammatory conditions within 10 years, and nearly 90% agreed current therapies mainly manage symptoms rather than root causes. The strongest interest centered on chronic inflammatory conditions in dogs and cats, including oral disease such as feline chronic gingivostomatitis, where Gallant is also advancing an off-the-shelf allogeneic stem cell product. (gallant.com)

Why it matters: For veterinary professionals, the survey is less a practice guideline than a signal about where clinical demand, client expectations, and industry investment may be headed. That matters because the field is still in a transitional phase: AVMA policy says regenerative medicine shows promise, but also stresses that evidence, validated protocols, donor screening, manufacturing controls, and FDA compliance remain essential, since definitive safety and efficacy data are still lacking for many indications. (avma.org)

What to watch: Watch for more peer-reviewed data, FDA milestones, and whether ready-to-use products for conditions like refractory feline chronic gingivostomatitis move closer to broader clinical availability. (pubmed.ncbi.nlm.nih.gov)